In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3399-3402

  Danova, Marco ^a   Bencardino, Katia ^a   Manzoni, Mariangela ^a   Grasso, Donatella ^a   Mariucci, Sara ^a   Rovati, Bianca ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Cell kinetics; Chemotherapy; Docetaxel; Epirubicin; Pegfilgrastim

Indexed keywords

DOCETAXEL; EPIRUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALOPECIA; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE PHASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FATIGUE; FEMALE; HUMAN; IN VIVO STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; TREATMENT RESPONSE; VOMITING;

ADULT; ANTIGENS, CD34; ANTIGENS, CD38; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; EPIRUBICIN; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELLS; HUMANS; MIDDLE AGED; NEUTROPENIA; TAXOIDS;

EID: 35348945335     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Marangolo M, Bengala C, Conte PF et al: Dose-response relationship: review of the past to improve the future of chemotherapy. Eur J Cancer 3(2): 365 (Abstr. 1267), 2005.
2. Budman DR: Dose and schedule as determinants of outcomes in chemotherapy for breast cancer. Semin Oncol 31(suppl 15): 3-9, 2004.
3. Citron ML, Berry DA, Cirrincione C et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8): 1431-1439, 2003.
4. Fornier M and Norton L: Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res 7(2): 64-69, 2005.
5. Vogel CL, Wojtukiewicz MZ, Carroll RR et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23: 1178-1184, 2005.
6. Danova M, Rosti V, Mazzini G et al: Cell kinetics of CD34-positive hematopoietic cells following chemotherapy plus colony-stimulating factors in advanced breast cancer. Int J Cancer 63: 646-651, 1995.
7. Rosti V, Bergamaschi G, Lucotti C et al: Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. Blood 86: 3387-3393, 1995.
8. Ferrari S, Danova M, Porta C et al: Circulating progenitor cell release and functional characterization after Topotecan plus G-CSF and erythropoietin in small cell lung cancer patients. Int J Oncol 15: 811-815, 1999.
9. Danova M, Porta C, Ferrari S et al: Cell cycle status and apoptosis of hematopoietic progenitor cells released into the peripheral blood after taxanes and granulocyte colony-stimulating factor in breast cancer patients. Oncol Rep 7: 585-589, 2000.
10. Gothot A, van der Loo CM, Clapp W and Srour E: Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34+ cells in non-obese diabetic/severe combined immune-deficient mice. Blood 92: 2641-2649, 1998.
11. Lemoli R, Tafuri A, Fortuna A et al: Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant granulocyte colony stimulating factor. Blood 89: 1189-1196, 1997.